The U.S. Food and Drug Administration (FDA) officially granted premarket approval (PMA) to Nyxoah for its flagship Genio system to treat adult patients with moderate to severe obstructive sleep apnea. This milestone permitted the company to initiate its targeted commercialization strategy across the United States, backed by robust clinical evidence from its pivotal DREAM trial demonstrating strong positional efficacy and safety.